The share of Russian drugs in VZN program reached a record level

In the 1st quarter of 2020 has sharply increased the share of domestic drugs procured by the state in the framework of the high-cost nosologies (VZN). Much of the growth is due to the switching of the state with the procurement of original drugs to generics production associated with “Pharmstandard” company “Generium”, writes “Kommersant”.

According to DSM Group in the 1st quarter of 2020 the Ministry of health of the Russian Federation has purchased in the framework of the WNV 2.5 million packages of drugs at RUB 31.9 billion growth compared to the same period last year increased modestly to 86.8% and 97.2%, respectively. The share of Russian drugs in the structure of procurement of WNV from January to March rose from 8.9% to 30% in monetary terms and from 29.2% to 42.7% in natural terms.

Growth occurred in this period, the replacement of a number of previously purchased original products at the Russian counterparts. So, with the purchase of the INN dornase Alfa for the treatment of cystic fibrosis of the original drug Pulmozyme (Roche) was replaced by Russian Tigeraso. At the INN-imiglucerase instead of Cerezyme Sanofi, the French state began to buy generic Purim. Eculizumab American Alexion under the brand name SOLIRIS to treat paroxysmal nocturnal hemoglobinuria was replaced by Russian drug Elizaria. All three of the generic are manufactured by Russian company “Generium”, whose founder is the owner of “Pharmstandard” Victor Haritonin.

According to the materials of public procurement, since the beginning of the 2020 procurement Tigerz amounted to RUB 1.3 billion, Purisima – 815,6 million rubles, Elizario – 3.2 billion rubles.

As reported by “Kommersant”the General Director of JSC “ROCHE-Moscow” Lars Nielsen, the company does not intend, in the light of recent changes to leave the Russian market, as purchases of “Pulmozyme” can still be implemented at the level of constituent entities of the Russian Federation in the framework of current legislation according to the decision of the medical Commission the product can be purchased not only at an INN, but at a name – so this year were sold around 600 packs of “Pulmozyme”.

According to the company “Generium”, she is currently implementing 25 projects for the development of drugs for the treatment of orphan diseases and cancer, and we are talking about both the generic and the original drug.

The rejection of the original procurement of drugs for the treatment of cystic fibrosis caused last year protests from patients ‘ organizations, points to the insufficient knowledge and possible severe side effects of of generics produced in Russia, among whom were “Theresa” of the “Generium”. The company argued that conclusions about the ineffectiveness of the drug was taken by patients hastily, before its introduction.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]